Therapy Areas: Inflammatory Diseases
argenx advances efgartigimod SC for idiopathic inflammatory myopathies
20 November 2024 - Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) confirmed on Wednesday that it will continue developing efgartigimod subcutaneous (SC) (efgartigimod alfa and hya...
Nektar Therapeutics announces 2024 ACR conference oral presentation of NKTR-422 preclinical data
19 November 2024 - US-based clinical-stage biotechnology company Nektar Therapeutics (Nasdaq: NKTR) announced on Monday its oral presentation highlighting preclinical data on NKTR-422 at the 2024 Amer...
Aldeyra Therapeutics' NDA for reproxalap in dry eye disease accepted by FDA; Partnership with AbbVie expanded
18 November 2024 - Biotechnology company Aldeyra Therapeutics Inc (Nasdaq: ALDX) announced on Monday that the FDA has accepted for review its New Drug Application (NDA) for reproxalap, an investigatio...
Adicet Bio doses first patient in Phase 1 trial of ADI-001 for lupus nephritis
18 November 2024 - Biotechnology company Adicet Bio Inc (Nasdaq: ACET) announced on Monday the first dosing of a lupus nephritis (LN) patient in its Phase 1 trial for ADI-001, an allogeneic gamma delt...
Carisma Therapeutics announces promising preclinical data on engineered macrophages for treating liver fibrosis at AASLD The Liver Meeting 2024
18 November 2024 - Clinical-stage biopharmaceutical company Carisma Therapeutics Inc. (Nasdaq: CARM) announced on Sunday promising preclinical data on engineered macrophages for treating liver fibrosi...
Sanofi seeks FDA approval for Dupixent in chronic spontaneous urticaria
15 November 2024 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the US Food and Drug Administration (FDA) has accepted a resubmitted supplemental bi...